Source: NuGen.
  • Common shares of NuGen Medical Devices (NGMD) have begun trading on the OTCQB under the symbol NGMDF
  • The company’s common shares will continue to trade on the TSX Venture Exchange under the symbol NGMD
  • Trading on the OTCQB will provide NuGen with added visibility to U.S. investors
  • The company also reports that it is awaiting approval for its application for DTC eligibility
  • NuGen is a specialty medical device company
  • NuGen Medical Devices (NGMD) is up 9.52 per cent on the day, trading at C$0.115 per share at 1:30 pm ET

Common shares of NuGen Medical Devices (NGMD) have begun trading on the OTCQB under the symbol NGMDF.

The company’s common shares will continue to trade on the TSX Venture Exchange under the symbol NGMD.

“Commencing trading on the OTCQB venture exchange is an important milestone for NuGen,” stated Michael Wright, CEO of NuGen.

“Having our common shares available on the OTCQB will increase accessibility for American investors interested in directly participating in NuGen’s growth with the same ease as their Canadian counterparts.”

The OTCQB Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their financial reporting and undergo an annual verification and management certification process.

The company also reports that it is awaiting approval for its application for DTC eligibility for electronic settlement and transfer of its common shares in the United States.

NuGen is a specialty medical device company developing needle-free technologies and other innovative medical delivery products.

NuGen Medical Devices (NGMD) is up 9.52 per cent on the day, trading at C$0.115 per share at 1:30 pm ET.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.